These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Incretin hormone secretion over the day. Ahrén B; Carr RD; Deacon CF Vitam Horm; 2010; 84():203-20. PubMed ID: 21094901 [TBL] [Abstract][Full Text] [Related]
5. The biology of incretin hormones. Drucker DJ Cell Metab; 2006 Mar; 3(3):153-65. PubMed ID: 16517403 [TBL] [Abstract][Full Text] [Related]
6. Replacing SUs with incretin-based therapies for type 2 diabetes mellitus: challenges and feasibility. Knop FK; Holst JJ; Vilsbøll T IDrugs; 2008 Jul; 11(7):497-501. PubMed ID: 18600596 [TBL] [Abstract][Full Text] [Related]
7. [The physiology of incretins]. Winkler G Orv Hetil; 2011 Nov; 152(48):1922-30. PubMed ID: 22167829 [TBL] [Abstract][Full Text] [Related]
8. Incretins: pathophysiological and therapeutic implications of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1. Ranganath LR J Clin Pathol; 2008 Apr; 61(4):401-9. PubMed ID: 18375745 [TBL] [Abstract][Full Text] [Related]
9. Incretin hormones: Their role in health and disease. Nauck MA; Meier JJ Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():5-21. PubMed ID: 29364588 [TBL] [Abstract][Full Text] [Related]
10. Incretin-based therapy and type 2 diabetes. Hare KJ; Knop FK Vitam Horm; 2010; 84():389-413. PubMed ID: 21094909 [TBL] [Abstract][Full Text] [Related]
11. Duodenal-jejunal bypass protects GK rats from {beta}-cell loss and aggravation of hyperglycemia and increases enteroendocrine cells coexpressing GIP and GLP-1. Speck M; Cho YM; Asadi A; Rubino F; Kieffer TJ Am J Physiol Endocrinol Metab; 2011 May; 300(5):E923-32. PubMed ID: 21304061 [TBL] [Abstract][Full Text] [Related]
12. Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin. Svendsen PF; Nilas L; Madsbad S; Holst JJ Metabolism; 2009 May; 58(5):586-93. PubMed ID: 19375579 [TBL] [Abstract][Full Text] [Related]
13. New physiological effects of the incretin hormones GLP-1 and GIP. Asmar M Dan Med Bull; 2011 Feb; 58(2):B4248. PubMed ID: 21299928 [TBL] [Abstract][Full Text] [Related]
14. Is there a place for incretin therapies in obesity and prediabetes? Holst JJ; Deacon CF Trends Endocrinol Metab; 2013 Mar; 24(3):145-52. PubMed ID: 23415157 [TBL] [Abstract][Full Text] [Related]
15. Current and emerging therapies: an overview of incretin-based therapy in the management of type 2 diabetes. Pratley RE J Am Acad Nurse Pract; 2008 Nov; 20 Suppl 1():7-11. PubMed ID: 19402254 [No Abstract] [Full Text] [Related]
16. K-cells and glucose-dependent insulinotropic polypeptide in health and disease. Cho YM; Kieffer TJ Vitam Horm; 2010; 84():111-50. PubMed ID: 21094898 [TBL] [Abstract][Full Text] [Related]
17. Dissociated incretin response to oral glucose at 1 year after restrictive vs. malabsorptive bariatric surgery. Guldstrand M; Ahrén B; Näslund E; Holst JJ; Adamson U Diabetes Obes Metab; 2009 Nov; 11(11):1027-33. PubMed ID: 19614945 [TBL] [Abstract][Full Text] [Related]
19. From the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents. Pei Z Curr Opin Drug Discov Devel; 2008 Jul; 11(4):512-32. PubMed ID: 18600568 [TBL] [Abstract][Full Text] [Related]
20. Nesfatin-1 stimulates glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide secretion from STC-1 cells in vitro. Ramesh N; Mortazavi S; Unniappan S Biochem Biophys Res Commun; 2015 Jun; 462(2):124-30. PubMed ID: 25930999 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]